NICE TA357: for treating advanced melanoma after disease progression with ipilimumab (Decision date - November 2015)
NICE TA366: for treating advanced melanoma not previously treated with ipilimumab (Decision date - December 2015)
NICE TA428: for treating PDL1-positive non-small-cell lung cancer after chemotherapy (Decision date - February 2017)
NICE TA519: for the treatment of locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (Decision date - May 2018)
NICE TA531: for untreated PD-L1 positive metastatic non-small-cell lung cancer (Replaces TA447) (Decision date - August 2018)
NICE TA553: for adjuvant treatment of resected melanoma with high risk of reoccurrence (Decision date - January 2019)
NICE TA600: with carboplatin and paclitaxel for untreated metastatic squamous NSCLC. (Decision date - October 2019)
NICE TA650: with axitinib for untreated advanced renal cell carcinoma. (Decision date - October 2020)
NICE TA661: for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. (Decision date - December 2020)
NICE TA683: with pemetrexed and platinum chemotherapy for untreated metastatic, non-squamous non-small-cell lung cancer (Replaces TA557) (Decision date - April 2021)
NICE TA709: for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (Decision date - July 2021)
NICE TA737: with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer. (Decision date - Nov 2021)
NICE TA766: for adjuvant treatment of completely resected stage 3 melanoma.(Decision date - March 2022)
NICE TA770: with carboplatin and paclitaxel for untreated
metastatic squamous non-small-cell lung cancer. (Decision date - March 2022)
NICE TA772: for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies. (Decision date - March 2022)
NICE TA801 - Pembrolizumab plus chemotherapy for untreated,
triple-negative, locally recurrent unresectable or metastatic breast cancer. NHSE
commissioned. (Decision date - July 2022)
NICE TA830 - Pembrolizumab for adjuvant treatment of renal cell carcinoma. (Decision date - November 2022)
NICE TA837 - Pembrolizumab for adjuvant treatment of resected stage 2B or 2C
melanoma. NHSE commissioned. (Decision date - November 2022)
NICE TA851 - Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. (Decision date - January 2023)
NICE TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer. (Decision date - July 2023)
NICE TA914 - Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (Decision date - October 2023)
NICE TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (replaces NICE TA885) NHSE commissioned.
NICE TA967 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over. NHSE commissioned (Decision date - June 2024)
SSC2685:NICE Technology Appraisal Final Draft Guidance: with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2- negative advanced gastric or gastro-oesophageal junction adenocarcinoma
DO NOT PRESCRIBE (DNP):
NICE TA540: for treating relapsed or refractory classical Hodgkin lymphoma (Decision date - October 2018)
NICE TA570: for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (Decision date - April 2019)
NICE TA674: for untreated
PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin
is unsuitable (terminated appraisal) (Replaces TA522) (Decision date - March 2021)
NICE TA692: for treating locally
advanced or metastatic urothelial carcinoma after platinum containing
chemotherapy (Decision date - May 2021)
NICE TA966 (Terminated Appraisal): for Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (Decision date - May 2024)
NICE TA983: for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma - Not recommended (Decision date - July 2024)
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
